The QualityStocks Daily Tuesday, November 28th, 2023

Today's Top 3 Investment Newsletters

MarketClub Analysis(RDHL) $2.2800 +128.00%

QualityStocks(ICCM) $1.3550 +83.11%

MarketBeat(CREV) $38.5000 +49.34%

The QualityStocks Daily Stock List

BrewBilt Manufacturing, Inc. (BBRW)

StockEarnings, QualityStocks, MarketClub Analysis, MarketBeat, Zacks, Schaeffer's and 247 Market News reported earlier on BrewBilt Manufacturing, Inc. (BBRW), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

BrewBilt Manufacturing, Inc. is one of the only California companies that custom designs, hand crafts, and integrates processing, fermentation, and distillation processing systems for the craft beer, cannabis, and hemp industries. The Company uses "Best in Class" U.S. made components integrated with stainless steel processing vessels using only American made steel. BrewBilt Manufacturing’s dedication is to helping build the craft beer community one brewery at a time. Founded in 2014, BrewBilt Manufacturing is headquartered in Grass Valley, California. The Company lists on the OTC Markets.

All BrewBilt Manufacturing products are designed and fabricated as "food grade" quality. This enables the Company to manufacture vessels for food & beverage processing. BrewBilt has been making systems that are pharmaceutical grade for clients involved in distillation for the cannabis and hemp industries over the past 36 months, thus making the revenue potential considerably greater.

The Company works with its clients every step of the way. This is from concept to opening. BrewBilt helps its clients keep on track. This is from working with their bankers on financing solutions, their architect and contractor on equipment layout, to scheduling, logistics, and continuing project management.

BrewBilt provides a six-year material and workmanship warranty on everything it builds. The BrewBilt team includes brewers, design engineers, craftsmen, and owners with greater than 50 years of business experience.

BrewBilt Manufacturing, Inc. (BBRW), closed Tuesday's trading session at $0.00055, up 175%, on 317,309,360 volume. The average volume for the last 3 months is 2.565M and the stock's 52-week low/high is $0.00005/$0.18.

IceCure Medical (ICCM)

QualityStocks, MarketClub Analysis, MarketBeat, Zacks, Schaeffer's and 247 Market News reported earlier on IceCure Medical (ICCM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

IceCure Medical Ltd (NASDAQ: ICCM) is a medical device firm that is engaged in the development and marketing of minimally invasive cryoablation therapies for the oncology and women’s health markets.

The firm has its headquarters in Caesarea, Israel and was incorporated in 2006. It operates as part of the medical equipment and supplies manufacturing industry. The firm serves consumers around the globe, with a focus on Israel, the United States, Europe, Singapore, Thailand and Hong-Kong.

The company is focused on advancing the treatment of cancerous tumors. Its proprietary 3rd generation technology makes the use of freezing temperatures i.e. liquid nitrogen, to effectively and safely destroy tumors, in a painless and quick way, thus eliminating the need for surgery.

The enterprise’s products include a cryoablation solution dubbed the ProSense System. This system uses ultrasound imaging to guide a small and thin hollow needle known as a probe into a tumor. The easy-to-use system allows the physician full control of the procedure and also cuts the procedure time short. This means that procedures can be conducted in less than half an hour, in the physician’s office. The system is a proven solution for treating benign breast tumors, which are known as fibroadenomas. This is in addition to being indicated for use in the fields of urology, gynecology, general surgery and oncology.

The company is focused on expanding the availability of ProSense globally. This is in addition to building out its clinical division and research and development division, as it creates next-generation cryoablation systems.

IceCure Medical (ICCM), closed Tuesday's trading session at $1.355, up 83.1081%, on 98,099,291 volume. The average volume for the last 3 months is 22.43M and the stock's 52-week low/high is $0.52/$4.73.

Aurora Cannabis Inc. (ACB)

InvestorPlace, Schaeffer's, MarketBeat, StocksEarning, MarketClub Analysis, The Street, Trades Of The Day, StockEarnings, Daily Trade Alert, StreetInsider, QualityStocks, The Online Investor, Wealth Insider Alert, Market Intelligence Center Alert, Kiplinger Today, StockMarketWatch, CFN Media Group, Investopedia, Stock Up Featured, Profit Trends, BUYINS.NET, BlackSwanAlert, StreetAuthority Daily, The Rich Investor, Jim Cramer, Early Bird, Investors Alley, Cannabis Financial Network News, Wall Street Window, CNBC Breaking News, Daily Profit, Tradespoon, Inside Trading, Outsider Club, TheTradingReport, Zacks, The Wealth Report, Market Intelligence Center, Technology Profits Daily, Money and Markets and Top Pros' Top Picks reported earlier on Aurora Cannabis Inc. (ACB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A new study has found that high schoolers are not as likely to use cannabis following the drug’s legalization. This finding weakens prior claims that youth who know or think that their friends, siblings or parents use cannabis may have a heightened risk for marijuana use and additional intervention and prevention strategies need to be implemented to reduce said risk.

The study, which was carried out by researchers at the University of Massachusetts Amherst, included associate professor Jennifer Whitehill of health policy and management and Public Health and Health Sciences doctoral candidate, Faith English. Whitehill’s focus, as the study’s senior author, was assessing whether the link between perceived cannabis use by friends and family, a risk factor for adolescent cannabis use, changed in the context of legalization.

For their study, the researchers conducted an analysis of data gathered from a pair of high schools in Massachusetts. They then compared data from two years: before marijuana was legalized and after retail stores were launched. They observed no significant difference in the prevalence of cannabis use in a 30-day period.

Among the participants surveyed prior to legalization, 27% and 19% of males and females respectively, reported that they used cannabis in the last 30 days. In the survey conducted after legalization, 28% and 20% of males and females respectively reported cannabis use in the last 30 days. They also observed that following legalization, the percentage of adolescents who reported that their parents used cannabis grew to 24% from 18%.

Currently, the recreational use of cannabis is fully legal in 24 states and the District of Columbia. In legal states, individuals aged 21 years and older are allowed to purchase and possess cannabis for recreational use. The researchers also discovered that perceived use of cannabis by a best friend, in comparison to perceived use by other parties, had the strongest link with cannabis use by teenagers.

The study’s findings can help inform public health guidelines and policy in the state of Massachusetts as well as other states rolling out marijuana laws.

English, who was the lead author of the study, is also interested in how legalization of marijuana influences youth contact with the justice system. In her dissertation, she assesses trends in marijuana-related discipline in a school setting and uses qualitative interviews with adolescents to understand their experiences with and perspectives on discipline in a school setting.

The study’s findings were reported in a special issue of “Clinical Therapeutics.

This study shows that opponents of legalization have no scientific basis to malign the entire cannabis industry, together with its leading players such as Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), for allegedly commercializing a product that would become increasingly accessible to kids. The data disproves such a claim.

Aurora Cannabis Inc. (ACB), closed Tuesday's trading session at $0.4656, off by 0.1287%, on 2,537,059 volume. The average volume for the last 3 months is 6.209M and the stock's 52-week low/high is $0.41/$1.48.

Seelos Therapeutics Inc. (SEEL)

QualityStocks, MarketBeat, StockEarnings, StockMarketWatch, MarketClub Analysis, TradersPro, Schaeffer's, BUYINS.NET, Trades Of The Day, Prism MarketView and INO Market Report reported earlier on Seelos Therapeutics Inc. (SEEL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Psychedelics have captured the scientific and mental-health communities’ attention due to extensive claims of their medical efficacy, particularly against hard-to-treat mental disorders. Several studies have connected psychedelics such as psilocybin (magic mushrooms), LSD and MDMA with significant and long-term improvements in mental health.

These studies have found that psychedelic therapy can be especially effective when it is paired with traditional psychotherapy and often induces profound and long-term benefits at small doses and with relatively few side effects. Even though the psychedelic field is still in the early research phase, results from clinical studies as well as anecdotal accounts have been so encouraging that an increasing number of Americans are choosing to microdose various psychedelics for health and wellness reasons.

People as diverse as everyday moms to high-level executives have dabbled in microdosing psychedelics in recent years. Many of them report improvements in creativity, focus and mental health as a result. Some folks are even using psychedelics to supplement their ADHD treatment in a move that could revolutionize how physicians perceive and treat attention-deficit hyperactivity disorder.

Studies indicate that taking small doses of hallucinogenic substances may alleviate some of the symptoms that affect people with ADHD and improve their mindfulness. These improvements seem to remain even when ADHD patients microdose psychedelics alongside conventional treatments, opening the door to new treatment protocols that leverage both psychedelics and pharmaceutical medications.

Pharmaceuticals such as Concerta, Ritalin and Adderall are often used to reduce hyperactivity and impulsivity in patients with ADHD. However, they rarely help adults with the condition deal with the challenges involved in living with ADHD, such as struggling to be present in the moment or dealing with emotional instability. In fact, some medications can even exacerbate symptoms such as stress and anxiety, which makes the day-to-day lives of adults with ADHD even more challenging.

Stacking psychedelics microdosing with prescription ADHD medications could allow patients to treat the classic impulsivity, hyperactivity and inability to focus associated with ADHD and alleviate poor mental-health symptoms. This could result in more comprehensive treatment protocols that would treat a much wider profile of symptoms and offer patients greater relief across the board.

A recent microdosing study that was published in the “Frontiers in Psychiatry Journal” found that psychedelic microdosers who had ADHD exhibited more levels of mindfulness and lower levels of emotional instability compared to the general population. The study also found that pharmaceutical ADHD medications did not affect psychedelics’ ability to improve mental health when stacked, indicating that both approaches offer separate therapeutic pathways. This could result in the development of personalized treatment protocols that use both pharmaceuticals and psychedelics to treat the full breadth of ADHD symptoms with no additional side effects.

With entities such as Seelos Therapeutics Inc. (NASDAQ: SEEL) studying the potential applications of psychedelics in treating a host of other mental -health conditions, the full extent of the medicinal value of these substances may yet expand beyond what is currently known.

Seelos Therapeutics Inc. (SEEL), closed Tuesday's trading session at $2.38, up 2138.95%, on 1,825,063 volume. The average volume for the last 3 months is 9.913M and the stock's 52-week low/high is $2.235/$49.80.

Freeport-McMoRan Inc. (FCX)

MarketClub Analysis, The Street, Schaeffer's, InvestorPlace, Kiplinger Today, SmarTrend Newsletters, StocksEarning, MarketBeat, Barchart, StreetAuthority Daily, Trades Of The Day, StreetInsider, Investopedia, Money Morning, TopStockAnalysts, QualityStocks, Daily Trade Alert, Zacks, Louis Navellier, VectorVest, Trading Markets, Marketbeat.com, The Growth Stock Wire, ProfitableTrading, Daily Wealth, The Wealth Report, Top Pros' Top Picks, Trading Tips, The Online Investor, StockEarnings, TheStockAdvisors, StreetAlerts, Wall Street Elite, All about trends, DividendStocks, Leeb's Market Forecast, Streetwise Reports, TradingMarkets, Market FN, Early Bird, INO.com Market Report, Dividend Opportunities, Investors Alley, TheStockAdvisor, InvestmentHouse, Investor Guide, StockTwits, Wealth Insider Alert, Investment House, Trading Concepts, Money and Markets, INO Market Report, Market Intelligence Center Alert, InvestorGuide, Options Trader Elite, The Best Newsletters, Cabot Wealth, Energy and Capital, Investing Signal, Buttonwood Research, Wyatt Investment Research, Wealth Daily, AnotherWinningTrade, Trade of the Week, The Motley Fool, Darwin Investing Network, Bourbon and Bayonets, Market Authority, Wealthpire Inc., Investor Update, Wall Street Daily, MarketWatch, Stock Research Newsletter, Street Insider, Profit Confidential, TradingAuthority Daily, Super Stock Investor, InvestorIntel, MiningNewsWire, AllPennyStocks, Rick Saddler, Uncommon Wisdom, InvestorsUnderground, Dynamic Wealth Report, WStreet Market Commentary, Daily Markets, CNBC Breaking News, 24/7 Trader, FNNO Newsletters, Normandy Investment Research, TradersPro, Weekly Wizards, FeedBlitz, Investiv, SmallCapVoice, Investment U, Inside Investing Daily, Weekly Market Strategies, Insider Wealth Alert, Inside Trading, Investing Daily, BUYINS.NET, Daily Profit, Profits Run, StreetAuthority Investor Update, Oakshire Financial, Navellier Growth, Money Wealth Matters, The Tycoon Report, ChartAdvisor, Stockhouse, Stock Barometer, Market Intelligence Center, Pennybuster, Greenbackers, Hit and Run Candle Sticks, Average Joe Options, Forbes, StockLockandLoad, TradingPub, Traders.com, Trader Prep, The Street Report, The Stock Dork, The Night Owl, The Daily Market Alert, Terry's Tips, Taipan Daily, Super Stock Picker, StreetAuthority Financial, Stocks To Watch, Penny Sleuth, StockMarketWatch, InsiderTrades, Stock Beast, SmallCap Network, Shah's Insights & Indictments, Schaeffer’s, PowerRatings Stocks, Penny Stock Buzz, Milestone Capital Growth Portfolio, MicroCap Gems, MarketTamer, Jason Bond, Investors Underground, Investors Daily Edge and StockRockandRoll reported earlier on Freeport-McMoRan Inc. (FCX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Top gold miners around the world have reported strong financial results for Q3 2023, thanks to a combination of lower mining costs and increasing gold prices that resulted in skyrocketing profits through the third quarter of the year. Growth in the global gold industry over the third quarter was so substantial that major miners were able to overcome depletion and maintain relatively stable collective output.

Some gold stocks registered the highest-ever growth in earnings amid high gold prices that are likely to attract institutional investment to the relatively struggling gold sector.

The mining industry as a whole has struggled to attract new investment in recent years. Gold has been especially affected as rising interest rates have drawn investor interest to other interest-paying segments. However, 2022 proved to be a plentiful year for the gold sector after several central banks around the world launched a massive gold-buying spree that lasted into 2023. While the sector has struggled to raise prices in the preceding months, the outbreak of hostilities between Hamas and Israel had a positive impact on gold markets.

The ongoing conflict has left many experts worried that it could trigger a broader war in the Middle East, disrupt the oil supply chain and plunge the global economy into chaos. These fears significantly increased the safe-haven appeal of gold and drew a large number of investors to the precious metal, causing gold prices in most markets to spike.

The industry’s dominant trading vehicle is still GDX VanEck Gold Miners ETF and its whopping $11.9 billion in net assets, which surpassed assets held by the second-largest major gold miner ETF by more than 31 times. GDX is clearly the most popular trading vehicle in the gold industry. Most of its weighting consists of gold from some of the sector’s largest players.

With more than 53% of the leading gold ETF comprising of miners that produce 250k+ and 500k+, the ETF’s largest miners reported fantastic results for the third quarter of the year. Even so, mid-tier and smaller miners will likely post even better results as their smaller production bases give them more room to consistently increase their outputs. Furthermore, their smaller market capitalizations allow for their stocks to be bid at higher prices faster than their larger competitors.

The gold industry as a whole seems to be shaking off recent issues such as surging inflation and rising production costs to maximize its profits. By weathering the recent headwinds, players in the gold industry such as Freeport-McMoRan Inc. (NYSE: FCX) have demonstrated their resilience and staying power.

Freeport-McMoRan Inc. (FCX), closed Tuesday's trading session at $37.22, up 1.7218%, on 11,345,441 volume. The average volume for the last 3 months is 467,987 and the stock's 52-week low/high is $32.825/$46.73.

Trulieve Cannabis Corp. (TCNNF)

InvestorPlace, MarketBeat, QualityStocks, Wealth Insider Alert, Daily Trade Alert, Top Pros' Top Picks, Cabot Wealth, The Street, Trades Of The Day, Profit Trends, TradersPro, The Online Investor and StreetInsider reported earlier on Trulieve Cannabis Corp. (TCNNF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Moving cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA) could have significant implications for medical cannabis recommendations by doctors and potential insurance coverage for marijuana treatments. Currently, doctors refrain from prescribing state-regulated medical cannabis due to the risk of losing their licenses given that it lacks approval from the U.S. Food and Drug Administration (FDA).

Even if the Drug Enforcement Administration (DEA) reschedules cannabis, the prohibition on doctors prescribing state-regulated medical marijuana (MMJ) products would persist. Nevertheless, doctors could continue to recommend non-FDA-approved cannabis products to individuals seeking MMJ cards, allowing them to register as marijuana patients in their states.

Moving cannabis to Schedule III would enable doctors to prescribe FDA-approved marijuana medicines. This would align with the current practice where physicians are authorized to prescribe Schedule III substances, such as Tylenol with codeine, only if they have FDA approval.

Leah Sera, codirector of the University of Maryland’s Graduate Studies in Medical Marijuana program, highlighted that physicians prescribing Schedule III substances would be a substantial change. However, she warned that the scope may not be as extensive as the current dispensary offerings. FDA approval would still be necessary, requiring marijuana drugs to undergo the approval process before prescription, sale and dispensing in pharmacies.

Rescheduling might stimulate increased research and development of marijuana-based drugs. However, the lengthy FDA approval process means that prescriptions for new cannabis-related products could be years away, according to Justin Brandt of the Bianchi and Brandt law firm.

Sera notes that while rescheduling won’t permit doctors to prescribe medical cannabis from state-licensed dispensaries, it could positively impact their attitudes toward the substance. “Rescheduling might not directly allow prescriptions for state-licensed dispensary products, but it could foster informed discussions between medical providers and patients about marijuana and its potential benefits and risks,” she stated.

Attorney Eric Berlin, an attorney at Dentons Law Firm, states that moving marijuana to Schedule III could also render FDA-approved cannabis products eligible for insurance coverage. Currently, insurance covers only FDA-approved drugs.

However, there are exceptions, as some states such as New York, New Mexico, New Jersey, New Hampshire, Minnesota and Connecticut allow workers’ compensation reimbursement for medical cannabis. In contrast, others do not obligate insurance carriers to reimburse for medical marijuana costs. Some states, such as Massachusetts, outright prohibit insurance coverage for medical cannabis.

Julie Schum of the Quintairos, Prieto, Wood and Boyer law firm noted that insurers might find covering medical marijuana more cost-effective than opiates since at least 30% of worker’s compensation claims involve opiate prescriptions. Such a decision would lead to a lot more insured people opting for medical cannabis products from enterprises such as Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) if they were sure insurance would cover the cost.

Trulieve Cannabis Corp. (TCNNF), closed Tuesday's trading session at $5.5, up 0.364964%, on 275,801 volume. The average volume for the last 3 months is 256,288 and the stock's 52-week low/high is $3.42/$16.11.

Astra Energy Inc. (ASRE)

QualityStocks and Green Energy Stocks reported earlier on Astra Energy Inc. (ASRE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Astra Energy (OTCQB: ASRE) today announced that it has retained toxic dilution funding expert attorney Mark R. Basile, Esq. and his RICO and securities litigation firm, The Basile Law Firm P.C. According to the announcement, the services to be provided include investigating recent activities surrounding the company’s stock performance and any potential RICO and Securities violations claims for all fundings taken by prior management over the last four years. “We are pleased to welcome Mr. Basile and his law firm, The Basile Law Firm P.C., to investigate claims of potential naked short selling of our security in connection to any prior dilution funding taken by the company,” said Ron Loudoun, CEO of Astra Energy. “Mr. Basile, a RICO and Securities dilution funding expert, has now been added to our top litigation team of attorneys and will be leading that part of our investigation and efforts.”

To view the full press release, visit https://ibn.fm/fkEpU

About Astra Energy Inc.

Astra is an integrated solutions provider investing in and developing clean and renewable energy projects in markets where demand is high, supply is limited and there is an opportunity to address other imminent market needs. Astra’s corporate strategy is rooted in securing technologies and assets; identifying viable market opportunities; and bringing together resources, expertise, technology, and defined action plans to execute first-in-class projects that benefit communities, local economies, the planet, and the company’s investors. Its goal is to create a more secure and sustainable power sector that supports the company’s purpose, mission and values to transform the economic, environmental and social landscape for generations to come. For more information on Astra Energy Inc., visit the company’s website at www.astraenergyinc.com.

Astra Energy Inc. (ASRE), closed Tuesday's trading session at $0.381, up 10.052%, on 226,298 volume. The average volume for the last 3 months is 412,825 and the stock's 52-week low/high is $0.0301/$0.455.

Elevai Labs (ELAB)

We reported earlier on Elevai Labs (ELAB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Elevai Labs Inc. (NASDAQ: ELAB) is a medical aesthetic firm focused on designing, manufacturing and marketing skincare products.

The firm has its headquarters in Newport Beach, California and was incorporated in 2020. Prior to its name change in December 2021, the firm was known as Reactive Medical Labs Inc. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers globally.

The company has created and continues to invent innovative science-driven efficacious topical skincare technologies for the medical dispense market. Its products are developed under a proprietary “source to skin” technology platform dubbed PREx, Precision Regenerative Exosome Technology. PREx is based on more than a decade of research and development by stem cell expert and biochemical engineer, Dr. Jordan Plews.

The enterprise’s products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. Both were developed to provide both post-treatment skin support and ongoing daily aftercare. Both products contain exosomes; ultra-small, nanoparticle compartments packed with growth factors known to support skin health. All of its products contain ELEVAI Exosome, which mimics the elegant repair process of nature along with a selection of high-quality actives to provide ongoing skin health for any skin type.

The company remains committed to revolutionizing how skin concerns related to aging and overall longevity of skin are addressed by providing consumers with next-generation products that are science-driven, efficacious, and at the leading edge of innovation. This may positively influence investments into the company as well as boost its overall growth.

Elevai Labs (ELAB), closed Tuesday's trading session at $4.04, up 1.5075%, on 343,773 volume. The average volume for the last 3 months is 6,666 and the stock's 52-week low/high is $3.10/$4.2442.

Anson Resources (ANSNF)

InvestorIntel reported earlier on Anson Resources (ANSNF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Anson Resources Limited (OTCQB: ANSNF) (ASX: ASN) (FRA: 9MY) is an exploration firm focused on acquiring, exploring for and developing mineral resources in Western Australia and the United States.

The firm has its headquarters in Brisbane, Australia and was incorporated in 2009, on April 17th. Prior to its name change in January 2016, the firm was known as Mayan Iron Corp. It operates as part of the other industrial metals and mining industry, under the basic materials sector. The firm serves consumers around the globe.

The company primarily explores for lithium, bromine, caustic soda, boron, and iodine; and zinc, lead, silver, graphite, nickel-cobalt laterite, vanadium, and uranium deposits. Its flagship property is the Paradox Basin Brine project, which covers an area of 167km2 and is located in the southeastern region of Utah, the United States of America. The company also holds an interest in a portfolio of three base metals and critical metals exploration projects, which include the Hooley Well cobalt-nickel laterite project, which covers an area of 154km2 and is located in Yilgarn Craton; the Bull nickel-copper-PGE project, which covers an area of 82km2; and the Ajana Springs project, which covers an area of 222km2. In addition to this, it holds an interest in the Yellow Cat project located in Thompson District, Utah.

The enterprise remains focused on advancing exploration at its projects and creating long-term shareholder value through the development of natural resources that can meet the demand of tomorrow’s new technology and energy markets.

Anson Resources (ANSNF), closed Tuesday's trading session at $0.0838, even for the day. The average volume for the last 3 months is 12,135 and the stock's 52-week low/high is $0.0741/$0.216909.

Collplant Biotechnologies (CLGN)

StockMarketWatch, MarketBeat, FreeRealTime, Zacks, StreetInsider, InvestorPlace and Daily Trade Alert reported earlier on Collplant Biotechnologies (CLGN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

CollPlant Biotechnologies Ltd (NASDAQ: CLGN) (FRA: CPT) is a regenerative and aesthetic medicine firm focused on 3D bioprinting of tissues and organs, and medical aesthetics.

The firm has its headquarters in Rehovot, Israel and was incorporated in June 2004 by Oded Shoseyov. Prior to its name change in June 2019, the firm was known as Collplant Holdings Limited. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers in the United States, Israel, Europe and Canada.

The company is party to collaboration agreements with CellInk, a BICO Group company; 3D Systems Corporation; Advanced Regenerative Manufacturing Institute; Tel Aviv University; RegenMed Development Organization; STEMCELL; Israel's Technion Institute of Technology; AbbVie; and Sheba Medical Center.

The enterprise’s products are based on recombinant type I human collagen that is produced with its proprietary plant-based genetic engineering technology. They include 3D Bioprinted breast implants for regeneration of breast tissue; dermal filler and soft tissue fillers for treating wrinkles; BioInks for 3D printing of tissues and organs; injectable implants to promote breast tissue regeneration; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; 3D bioprinted regenerative soft tissue matrix; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, bedsores, burns, venous and pressure ulcers, and other chronic wounds.

The firm, which is set to announce its latest financial results, remains committed to delivering ground-breaking products for regenerative medicine that offer the optimal treatment options to patients. This may improve the quality of life of patients while also encouraging additional investments into the firm.

Collplant Biotechnologies (CLGN), closed Tuesday's trading session at $5.7301, up 1.4177%, on 8,231 volume. The average volume for the last 3 months is 12,106 and the stock's 52-week low/high is $4.57/$13.97.

BranchOut Food (BOF)

InsiderTrades and 247 Market News reported earlier on BranchOut Food (BOF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

BranchOut Food Inc. (NASDAQ: BOF) is a food technology firm focused on developing, marketing, selling and distributing plant-based dehydrated fruit and vegetable snacks and powders in the United States.

The firm has its headquarters in Bend, Oregon and was incorporated in November 2017 by David Israel and Eric Healy. Prior to its name change in November 2021, the firm was known as Avolov LLC. It operates as part of the packaged foods industry, under the consumer defensive sector. The firm mainly serves consumers in the U.S.

The enterprise has licensed the rights to a new dehydration technology designed for drying and processing sensitive fruits and vegetables such as avocados, bananas and others. Its products include BranchOut Powders, BranchOut Snacks, and BranchOut Industrial Ingredients. Its BranchOut Powders include Avocado Powder, Banana Powder and Blueberry Powder while its BranchOut Snacks include dehydrated fruit- and vegetable-based snacks, including Avocado Chips, Brussels Sprouts Crisps, Chewy Banana Bites, Pineapple Chips and Bell Pepper Crisps. On the other hand, the enterprise’s BranchOut Industrial Ingredients include Bulk Avocado Powder, dried avocado pieces and other fruit powders/pieces. It is also developing additional products, including chocolate-covered fruit items and various private label products for large retailers.

The company recently announced its latest financial results, which show significant increases in its full year revenues. It is currently focused on ramping up production to help meet the rising demand from its retailer partners and bolstering its overall growth. This may in turn bring in additional revenues while also encouraging additional investments into the company as well.

BranchOut Food (BOF), closed Tuesday's trading session at $1.58, up 8.2192%, on 2,879 volume. The average volume for the last 3 months is 19,817 and the stock's 52-week low/high is $1.32/$6.20.

Acrivon Therapeutics (ACRV)

MarketBeat reported earlier on Acrivon Therapeutics (ACRV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Acrivon Therapeutics Inc. (NASDAQ: ACRV) is a clinical-stage biopharmaceutical firm focused on the development of oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine through the use of its proteomics-based patient responder identification platform.

The firm has its headquarters in Watertown, Massachusetts and was incorporated in 2018 by Kristina Masson and Peter Blume-Jensen. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the globe.

The company’s Acrivon Predictive Precision Proteomics, a precision medicine platform, enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.

The enterprise’s lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. It has received fast track designation from the FDA for the investigation of ACR-368 as a monotherapy based on OncoSignature-predicted sensitivity in patients with platinum-resistant ovarian or endometrial cancer. It is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. Its development candidate, ACR-2316, is a selective, dual WEE1/PKMYT1 inhibitor.

The firm, which recently announced its latest financial results, remains committed to advancing its clinical and preclinical pipeline of precision oncology medicines. This is in addition to generating additional value for its shareholders.

Acrivon Therapeutics (ACRV), closed Tuesday's trading session at $3.88, up 1.5707%, on 21,871 volume. The average volume for the last 3 months is 186,233 and the stock's 52-week low/high is $3.4113/$25.47.

The QualityStocks Company Corner

Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF)

The QualityStocks Daily Newsletter would like to spotlight Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF).

Appia Rare Earths & Uranium (CSE: API) (OTCQX: APAAF) (FSE: A0I0), a Canadian company in the rare earth element and uranium sectors, has discovered an unprecedented high-grade mineralized zone at its PCH Ionic Clay project in Brazil. According to the announcement, the discovery shows a total weighted average grade of 7,578 ppm or 0.76% total rare earth oxide across 10 reverse circulation ("RC") drill holes. This information is the result of the further delineation of the SW Extension Zone, a significant high-grade rare earth elements ("REE") mineralized zone located in the southwest corner of the Target IV zone of the project. The announcement, which builds on previous PCH-RC-63 results, noted that the discovery spans an area of more than 1,000 meters by 500 meters, with an average thickness of approximately 19 meters. The lateral extension and the depth of the SW Extension zone has not been fully tested, with results still to come from the remaining seven RC holes drilled within this new zone as well as the numerous RC drill holes located outside of the Target IV boundary to the south. The PCH project, which is more than 17,000 hectares in size, is situated within the Tocantins Structural Province in the Brasília Fold Belt. "We believe that the high-grade nature of the SW Extension Zone, which contains magnet rare earth oxides sample values of up to 13,212 ppm, or 1.32%, places this discovery on a global stage," said Appia Rare Earths & Uranium CEO Tom Drivas in the press release. "The fact that all of these holes are still open at depth creates an opportunity to discover additional mineralization at depth."

To view the full press release, visit https://ibn.fm/QCuSw

Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF) is a mineral exploration company focused on exploration activities at its newly acquired Cachoeirinha rare earths project (“PCH Project”) in Brazil, as well as delineating high-grade critical rare earth elements (REE) and gallium at its Alces Lake property in Saskatchewan. Other properties in Appia’s portfolio include its Elliot Lake Property in Ontario’s historic mining camp, with a large NI 43-101 uranium and rare earths resource. Fully funded with over $5 million (CDN) in cash, no debt, aggressive exploration currently underway, and experienced management, Appia is progressing rapidly on multiple fronts in highly desired market sectors.

The company is headquartered in Toronto, Canada.

Projects

PCH Project-Brazil

The PCH project hosts REE mineralization in both ionic clays developed from the weathering of alkaline granites and in-situ rare earth mineralization associated with the underlying granite and a carbonatite intrusion to depths greater than 100 meters. Sampling data shows enrichment in rare earth minerals to depths of between eight meters and +30 meters.

In early 2023, Appia announced a definitive agreement to acquire a 70% interest in the PCH Project, which is 17,551 hectares in size and located in the Tocantins Structural Province of the Brasília Fold Belt, Goiás State, Brazil. It is classified as an alkaline intrusive rock occurrence with the potential for highly anomalous REE and Niobium mineralization.

The region around Iporá, a city located roughly 30 km from the PCH Project, has significant mineral exploration and mining activity and well-developed infrastructure.

In July 2023, Appia commenced an aggressive auger and reverse circulation (RC) drill campaign to delineate a potential resource estimate at the PCH project. Initial results at the site revealed significant exploration potential with impressive values that often surpass known ionic clay deposits in Brazil, particularly for the highly valuable heavy rare earths Terbium and Dysprosium.

The auger holes drilled at Target 4 have exhibited a range of total REE grades, ranging from 274 ppm to 16,648 ppm (1.66%), with an average of 1,291 ppm total REE. The valuable rare earths used in magnet applications – praseodymium, neodymium, terbium and dysprosium (Pr, Nd, Tb, and Dy) plus yttrium (Y) accounted for approximately 14% of total rare earths, reaching a maximum of 28.4%. Notably, the deposit also contains anomalous values of niobium and scandium, with average values of 736 ppm for Nb and 62 ppm for scandium in a composite sample from Target 4.

Heavy rare earths (HREEs) show maximum values of 1,624 ppm and average values of 1,291 ppm, primarily as terbium and dysprosium. Light rare earths (LREEs) show maximum values of 14,024 ppm (1.54%) with an average of 1,145 ppm. Neodymium and praseodymium, the main magnetic light rare earths, show respective maximum values of 3,131 ppm (Nd) and 885 ppm (Pr) and average values of 216 ppm (Nd) and 61.7 ppm (Pr). The overall HRRE/LREE ratio has a maximum of 39.5% and an average value of 16.67%.

“Appia is thrilled with the progress made and the promising results thus far,” CEO Tom Drivas stated in a news release. “The company remains committed to advancing its exploration plans, aiming to promptly gather significant data throughout the year, and to work towards estimating a maiden mineral resource in the coming months.”

Alces Lake Project – Saskatchewan

Appia’s Alces Lake project, located in northern Saskatchewan, encompasses some of the highest-grade total and critical REEs and gallium mineralization in the world, hosted within several surface and near-surface monazite occurrences that remain open at depth and along strike.

Following the company’s acquisition of additional new mineral claims in the area in February 2023, Appia’s Alces Lake claim block now totals 38,522 contiguous hectares (95,191 acres) – 100% owned by the Company.

Appia announced the completion of a NI43-101 technical report on the property in June 2023, providing an update on exploration previously reported in March 2021.The report is available on SEDAR under the company’s profile.

Extensive diamond drilling and geophysics surveys are underway to explore a more than 25-kilometer structural corridor. In July 2023, the company issued an update on its diamond drill program having completed the first phase of drilling at the project’s Magnet Ridge Zone to further test the extent of the mineralization to the south south-east (SSE). President Stephen Burega noted the presence of “continued mineralization at significantly thicker intercepts.”

As part of its 2023 exploration program at Alces Lake, Appia plans to target priority areas that extend SSE from the Wilson, Richard, Charles, Bell, Ivan, Dylan, Dante and AMP zones through the Magnet Ridge Zone and beyond, covering an area extending approximately 20 kilometers in length and 5 to 7 km in width. Appia will also undertake reconnaissance drilling on priority regional geological and geophysical targets in the Western Anomaly area.

Other Projects

  • Appia holds a total of 75,314 hectares (186,106 acres) of land on four uranium claim blocks in the prolific Athabasca Basin (Loranger, North Wollaston, Eastside and Otherside). Exploration plans for these properties are expected to be announced once permits are in hand.
  • Appia also has a 100% interest in 12,545 hectares (31,000 acres), with rare earth element and uranium deposits over five mineralized zones, in the Elliot Lake Camp, Ontario.

Market Opportunity

A report from Mordor Intelligence forecasts the global REE market is expected to grow from 168 million tons in 2023 to 206.25 million tons by 2028, marking a CAGR of 4.19% during the forecast period. The market is gradually improving following the economic and production restrictions of the COVID-19 pandemic.

Factors driving the market’s growth include high demand from emerging economies and the dependency of environmentally friendly technologies on rare earth elements.

According to UxC, one of the nuclear industry’s leading market research and analysis companies, the uranium market is rapidly becoming production-driven, where spot and long-term prices more closely correlate to the marginal cost of uranium production.

Although global reactor requirements are projected to be flat through 2024, UxC forecasts that significant demand growth from 2025 to 2040 will necessitate new production as resources are exhausted at several uranium projects. In addition, a large percentage of production exists in regions of the world with high geopolitical risk, which makes the market vulnerable to future disruptions and price volatility.

Management Team

Tom Drivas is CEO of Appia Rare Earths & Uranium Corp. He is an entrepreneur with over 30 years of experience in various industries, including over 20 years in the mineral resource industry. He is also currently a director of Romios Gold Resources Inc., a publicly traded company he founded in 1995.

Stephen Burega is President of Appia. He brings 16 years of management and operations experience in the mining and natural resources sectors. His extensive emerging markets background, along with a deep understanding of stakeholder management, social development and structured community engagement, position him well to lead Appia’s First Nations community engagements. He is also President and CEO of Romios Gold Resources which is focused on base and precious metal exploration in North America.

Frank van de Water is the company’s CFO. He holds CPA and CA designations and has been involved with international mining, metals and resource companies in North America, Latin America, Europe and Africa for more than 40 years.

Dr. Irvine R. Annesley, Ph.D., is VP Exploration at Appia. He is a licensed geoscientist (P.GEO.) and Professor in Economic (Mining and Mineral Exploration) Geology at École Nationale Supérieure de Géologie in France and an Adjunct Professor in Geology at the University of Saskatchewan. He has over 35 years of global exploration and applied research experience in uranium, gold and base metals exploration, most recently with Athabasca uranium explorer JNR Resources Inc.

Don Hains, P.Geo., is the company’s Consulting Geologist and Qualified Person Consulting Industrial Minerals Expert.

Antonio Vitor is Appia’s Country Manager, Brazil. He has a track record as a portfolio manager and board member. He has held multiple significant positions, including Territory Manager at Shell, as well as Senior Project Planning and Consulting roles at PwC and Petrobras.

Jack Lifton is the company’s Senior Technical Advisor and Consultant. He is an author and lecturer on the market fundamentals of technology metals.

Appia Rare Earths & Uranium Corp. (OTCQX: APAAF), closed Tuesday's trading session at $0.21814, up 9.07%, on 196,090 volume. The average volume for the last 3 months is 6,267 and the stock's 52-week low/high is $0.075/$0.3044.

Recent News

Starco Brands Inc. (OTCQB: STCB)

The QualityStocks Daily Newsletter would like to spotlight Starco Brands Inc. (OTCQB: STCB).

Starco Brands, Inc. (the "Company" or "Starco Brands") (OTCQB: STCB), developer and acquirer of behavior-changing technologies and brands that spark excitement in the everyday, today announced that Ross Sklar, the Company's Chairman & CEO, will present at the following investor conferences:

SHARE Series Event , to be held virtually on December 4, 2023. Mr. Sklar will participate in a fireside chat at 2:30PM ET and investors will have the opportunity to ask questions during the chat. The fireside chat will be webcast live and can be accessed here or in the "IR Calendar" section of the Company's Investor Relations website at https://investors.starcobrands.com .

Emerging Growth Conference , to be held virtually on December 6-7, 2023. Mr. Sklar will hold a presentation at 1:45PM ET on December 6, 2023 and may subsequently open the floor for questions. Please submit your questions in advance to Questions@EmergingGrowth.com or ask your questions during the event. The presentation will be webcast live and can be accessed here or in the "IR Calendar" section of the Company's Investor Relations website at https://investors.starcobrands.com .

Starco Brands Inc. (OTCQB: STCB) is a modern-day invention factory. The company’s unwavering mission is to invent and acquire consumer products and brands with behavior-changing technologies that spark excitement in the everyday.

This consumer product company has grown from a few million dollars in revenue to a current run rate of approximately $67 million in annual revenue in one year.

The company has succeeded by identifying whitespaces in eight core consumer categories and then either: 1) leveraging its internal R&D capabilities and dedicated manufacturing network to invent new technologies and brands or 2) utilizing the management team’s extensive M&A experience to acquire brands that fill the industry void, delighting consumers and retailers alike.

Whether the brand is developed internally or acquired, the company employs a modern marketing playbook to ensure its brands are at the forefront of culture; garnering unprecedented media attention and engagement that supports a robust sales network.

Starco Brands’ core competencies are inventing technologies, acquiring companies, marketing, building trends, pushing awareness, penetrating media (social and otherwise) and executing cutting edge pull-through strategies with a roster of globally recognized celebrities, influencers and media and distribution partners.

A commitment to changing the way people approach everyday activities is innate in the company’s corporate DNA.

The company is based in Santa Monica, California.

Brands

Whereas other consumer products companies are content with evolution, Starco Brands has its mind set on creating a revolution across the industry. From disrupting the spirits industry with Whipshots, the world’s only vodka-infused whipped cream, to Soylent, the original food tech company, Starco Brands is putting the CPG world on notice. Its portfolio of brands includes:

  • Whipshots is a first-of-its-kind alcoholic whipped cream launched in 2021 with celebrity partner Cardi B. Consumers have embraced this boozy concoction, putting it on top of cocktails, coffees and desserts, or enjoying it straight from the can. In just over a year, the brand has sold over 2 MILLION cans, making it one of the fastest growing spirits in history.
  • Winona Pure gives consumers movie theatre popcorn in the comfort of their own homes. All the flavor and none of the additives is the story behind these all-natural, non-GMO popcorn seasoning sprays. A simple spray is all it takes to add the perfect pop of flavor to the classic theatre treat.
  • Art of Sport, co-founded by the great Kobe Bryant, is the number one body care brand for athletes. With a growing line of personal care products tested by the world’s greatest athletes, these daily skin essentials give consumers everything they need to feel fresh, stay protected and confident and perform at their peak every day.
  • Skylar is the first and only line of perfumes on the market that are hypoallergenic and safe for sensitive skin. With the strong support of industry titan Sephora, the brand has quickly attracted a loyal following.
  • Soylent is a technological feat. Originally funded by Google Ventures and Andreessen Horwitz, Soylent is dubbed as the world’s most perfect food. Made from sustainably grown plant-based ingredients, Soylent’s line of products is scientifically developed to provide all the functional ingredients, vitamins, minerals, fats, carbohydrates and protein that the body needs – all in convenient, delicious and affordable packages. Soylent’s innovative product line-up includes complete nutrition powders, ready-to-drink shakes, 100-calorie snack bars, high protein nutrition shakes and energy boosting nutrition shakes. Soylent was also the recipient of the 2023 Product of the Year Award by Kantar, a global leader in consumer research.

With award-winning marketing talent, Starco Brands develops robust, integrated marketing plans for every brand in its portfolio, ensuring an impactful presence across all verticals.

Market Outlook

Starco Brands’ varied brand portfolio gives it access to the growth of numerous product categories that are ripe for innovation.

Through its February 2023 acquisition of complete nutrition pioneer Soylent, Starco Brands is positioned to capitalize on the projected growth of the plant-based nutrition space. Research firm Statista valued the plant-based nutrition market at $29.4 billion in 2020 and forecasts its value at nearly $162 billion by 2030, representing a CAGR of 18.7% for the period.

Likewise, Starco Brands gained improved access to the global fragrance market through its December 2022 acquisition of Skylar. According to a report by Grand View Research, the global perfume market was valued at $50.85 billion in 2022 and is expected to grow to a value of nearly $80 billion by 2030, achieving a CAGR of 5.9% over the forecast period.

The company is primed to expand its access to other growth verticals as it advances on its path to invent and acquire behavior-changing technologies and brands.

Management Team

Ross Sklar is the CEO of Starco Brands. A chemical formulator by trade, he started his first company while still in college. Since 2004, he has made over a dozen acquisitions with multiple exits and controls an eclectic collection of industrial, household, personal care and food and beverage manufacturers covering many consumer-packaged goods categories.

Darin Brown is the Chief Operating Officer of Starco Brands. With over 20 years of experience in chemical manufacturing, business development, finance and mergers and acquisitions, he has scaled the company from the ground up. He oversees all internal operations for Starco Brands and is an integral liaison between the company and Mr. Sklar’s manufacturing facilities.

David Dreyer is Chief Marketing Officer of Starco Brands. With over 25 years of experience working with blue chip and startup brands, he oversees all marketing initiatives for the company. Mr. Dreyer comes to Starco having worked with such standout brands as Apple, Pepsi, Pizza Hut, Dr Pepper, Snapple, Infiniti, The GRAMMY’s, Honda and Stamps.com. He is also a Professor of Advertising at USC’s Annenberg School for Communication.

Starco Brands Inc. (STCB), closed Tuesday's trading session at $0.13, up 4%, on 500 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.3044/$.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is reporting additional positive interim results from its human pilot study evaluating DehydraTECH(TM) technology for the oral delivery of the glucagon-like peptide-1 ("GLP-1") drug semaglutide, available commercially as Rybelsus(R). According to the report, DehydraTECH-powered semaglutide sustained lower levels of blood glucose from baseline including nearly 10 times lower after 24 hours as well as lower blood-glucose spikes after eating. The company noted that this was the first-ever DehydraTECH test with a "large molecule" drug. According to the report, the study was conducted by a prominent university research center comparing a single 7 mg semaglutide dose of a Rybelsus tablet (the control dose) to a matching dose from Rybelsus that had been compound formulated in capsule form using Lexaria's DehydraTECH processing technology enhancements. Specifically, the control group showed reduced blood glucose levels by between 1.3% and 6.7% relative to the time zero baseline during the first 100 minutes of the study with the DehydraTECH GLP-1 group indicating reduced blood glucose levels by between 2.9% and 14.6% relative to baseline during that same timeframe; the report noted that even 24 hours after dose administration, the blood glucose levels were reduced in the DehydraTECH GLP-1 group by 6.3% relative to baseline while the blood glucose level evidenced in the control group was only reduced by 0.67%, evidencing nearly a tenfold improvement with the DehydraTECH GLP-1. DehydraTECH is a patented drug delivery formulation and processing platform technology. Lexaria developed the technology and is evaluating it for a variety of beneficial molecules. The formulation is designed to improve the way active molecules enter the bloodstream upon oral ingestion.

To view the full press release, visit https://ibn.fm/dbz43

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has also collaborated with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has been granted patent protection for specific delivery of nicotine, vitamins, NSAIDs, antiviral drugs, cannabinoids and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Tuesday's trading session at $1.6, off by 1.8405%, on 200,484 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.6488/$3.5953.

Recent News

SenesTech Inc. (NASDAQ: SNES)

The QualityStocks Daily Newsletter would like to spotlight SenesTech Inc. (NASDAQ: SNES).

SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal pest populations, has launched its Evolve(TM) Soft Bait product at Ace Hardware franchise locations in California; the franchise also began selling SenesTech's Isolate(TM) bait system. According to the announcement, this is the first time a traditional retail store has carried SenesTech rodent fertility control solutions. Evolve is the first and only soft bait product featuring breakthrough, next-generation technology designed to decrease rodent populations through nonlethal methods. "California-based Scarborough Ace Hardware, as well as Scarborough Home and Garden, are the first retail outlets to commit to SenesTech's line," said SenesTech president and CEO Joel Fruendt in the press release. "They will also be among the first in the U.S. to receive shipments of Evolve based on their recent preorder. We expect the penetration of retail and big box to rapidly accelerate, especially with the launch of Evolve and its retail-friendly soft bait profile and packaging. Evolve was developed to offer customers a soft bait product that has similar efficacy to ContraPest but in a format that is easier to deploy, and is ideally suited for use by do it yourself consumers. We are pleased to be partnering with the team at Scarborough Ace Hardware to provide their customers with an innovative solution to address their rodent issues."

In addition, SenesTech also announced the pricing of its public offering. According to the announcement, the offering is comprised of 3,846,154 shares of its common stock (or prefunded warrants in lieu thereof) and accompanying Series D warrants to purchase up to 3,846,154 shares of its common stock (Series D warrants) and Series E warrants to purchase up to 3,846,154 shares of its common stock (Series E warrants, together with Series D warrants, collectively the series warrants). The offering is at a combined price of $1.30 per share of common stock (or prefunded warrant in lieu thereof) and associated series warrants. The announcement noted that the series warrants, which will be immediately exercisable upon issuance, have an exercise price of $1.30 per share. Series D warrants will expire five years following the initial exercise date with Series E warrants set to expire 18 months following the initial exercise date. The public offering should close on or about Nov. 30, 2023, and is subject to customary closing conditions. Gross proceeds from the offering are anticipated to total an estimated $5 million before standard agent's fees and other offering expenses are deducted. SenesTech plans to use the proceeds from the offering for general corporate purposes, including R&D, capital expenditures, working capital and general and administrative expenses, as well as potential acquisitions or investments.

To view the full press release, visit https://ibn.fm/OaX9b and https://ibn.fm/6ti5m

SenesTech Inc. (NASDAQ: SNES) is the rodent fertility control expert and the inventor of the only EPA-registered contraceptive for male and female rats. The company’s technology provides an innovative and humane method for managing rat populations.

SenesTech is focused on developing effective solutions that are grounded in science and proven through research, all while providing value to people, communities and the environment. The company’s passion is to create a healthier world by better controlling rat pest populations. This aim is critical, as, if left unchecked, a breeding pair of rats and their descendants can produce up to 15,000 pups after just one year.

The company strives for clean cities, efficient businesses and happy households – with a product that was scientifically designed to be effective without killing rats. SenesTech is committed to the sustainable, humane treatment of animals, improving the quality of all human life and enhancing environmental stewardship through the global application of its effective solution in fertility control technology.

SenesTech is headquartered in Phoenix, Arizona.

ContraPest®

SenesTech’s first product, ContraPest®, applies revolutionary technology to a global challenge that has persisted since the Middle Ages – the proliferation of rats in urban and agricultural settings. ContraPest® targets the reproductive capabilities of Norway and roof rats. As a highly palatable liquid, the formulation promotes sustained consumption, helping to reduce fertility in both male and female rats, bringing populations down and keeping them down.

The company’s flagship offering can be used as part of integrated pest management (IPM) programs – fitting seamlessly into all IPM programs – to help reduce reproduction and magnify the success of these protocols, or as a standalone solution for customers who want to reduce or eliminate the use of lethal rodent control methods.

In multiple, independent field deployments, ContraPest was shown to reduce rat activity over 90% when added to an existing IPM program.

ContraPest® is registered federally as a General Use Product.

Delivery Systems and New Products

In July 2023, SenesTech began to distribute a new delivery system for ContraPest®, the Isolate Bait System™. This new delivery system brings to market a simple design that enables more efficient deployment, incorporates an enhanced formulation of ContraPest® that is expected to provide improved performance of the fertility control bait in the field and is paired with a new bait station that is more space-efficient and economical.

The other delivery systems available for ContraPest include the Ultimate Bait System™, a tank and tray in a larger format for use with more severe infestations, and the Elevate Bait System™, a unique delivery system that targets above ground infestations, as with roof rats.

SenesTech, as of August 2023, is also in the final stages of releasing a soft bait formulation, which provides the unique attributes of proven fertility control in an industry-familiar format demanded by big box retailers, key e-commerce channels and leading industry pest management professionals.

Market Opportunity

According to SenesTech’s figures, rats cause over $27 billion in damage to public and private infrastructure annually in the United States. Rats also destroy 20% of the global stored food supply every year by consuming or contaminating it.

Rats are known to spread at least 35 diseases, globally posing a dangerous risk to public health and safety. Not only does this age-old problem persist despite extensive campaigns to eradicate it, but multiple sources have reported that post-COVID rat populations have boomed.

Poison-based control methods sicken rats, and they typically die slowly. An animal that eats a poisoned rat may also sicken or die. The global rodenticide market is projected to be worth $1.7 billion by 2026.

In one case study, results reported by the customer showed a $5,000 investment in ContraPest® saved more than $500,000 annually in reduced labor, loss and damage.

Management Team

Joel Fruendt is SenesTech’s President and CEO. He has 15 years of executive leadership in the vector and pest control industries as Vice President and General Manager of Clarke Environmental Inc., a leading vector and pest control products and services company. He has extensive expertise in the development and manufacturing of EPA-registered chemical control products, and the commercialization and sale of those products. He received the ‘Smart Leaders’ award from Smart Business Magazine and holds a bachelor’s degree in business from Illinois Wesleyan University.

Tom Chesterman is CFO at SenesTech. He has over 20 years of experience as the CFO of public companies in the life science, tech and telecommunications industries. Most recently, he was the Vice President and Treasurer of GCI, a telecommunications company. Previous to that, he was the CFO of life science companies Bio-Rad Laboratories, Aradigm and Bionovo. He has a bachelor’s degree from Harvard University and an MBA from the University of California at Davis.

Dan Palasky is Chief Technical Officer at SenesTech. Previously he held the title of Vice President of Research & Development at PLZ Corp., a manufacturer of chemical consumer products, serving as the technical expert for its entire product portfolio. He started his career with Camie-Campbell, Inc., as a chemist in the R&D department. Mr. Palasky received his bachelor’s degree in chemical engineering from the Missouri University of Science & Technology and his MBA in Project Management from Aspen University.

SenesTech Inc. (NASDAQ: SNES), closed Tuesday's trading session at $0.93, off by 50.5319%, on 2,145,488 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.8706/$80.952.

Recent News

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI)

The QualityStocks Daily Newsletter would like to spotlight Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI).

Autoimmune diseases occur when the immune system becomes dysfunctional and begins attacking healthy tissue and organs. More than 20 million Americans suffer from a myriad of autoimmune diseases, such as thyroid disease, rheumatoid arthritis and lupus, that can significantly impact their quality of life. Many autoimmune patients often have to deal with years of misdiagnosis and untreated symptoms before they finally receive a proper diagnosis. Since a majority of autoimmune diseases have no cure, patients such as Beth VanOrden from Athens, Texas, have to take various medications to manage symptoms for the rest of their lives. VanOrden suffers from Hashimoto's disease, an autoimmune disorder that results in a condition called hypothyroidism, which impacts the production of metabolic hormones in the body. As enterprises such as Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) make progress in their R&D programs, effective immunotherapy treatments for autoimmune diseases could become readily available to the patients who need them.

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, Scinai is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. Scinai is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, Scinai has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, Scinai signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. Scinai anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of Scinai’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

Scinai has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, Scinai will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. Scinai anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

CDMO Services

While NanoAb pipeline development is Scinai’s core focus, the company also offers its cGMP manufacturing facility, aseptic fill and finish suite, laboratories and experienced professionals for contract development and manufacturing organization (CDMO) services. This offering is designed to keep the Scinai team abreast of the latest industry developments and trends while building experience and generating revenue to support the company’s NanoAb pipeline development.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future Scinai drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is Scinai’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at Scinai. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at Scinai. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining Scinai, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at Scinai. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to Scinai through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), closed Tuesday's trading session at $0.63, off by 0.000159%, on 9,308 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.501/$11.49.

Recent News

SuperCom Ltd. (NASDAQ: SPCB)

The QualityStocks Daily Newsletter would like to spotlight SuperCom Ltd. (NASDAQ: SPCB) .

SuperCom, a global leading provider of traditional and digital identity solutions, just reported a 550% growth in EBITDA and a 74% growth in gross profit margin for Q3 2023

Gross profit also saw an 89% YOY growth, and revenue YOY increased to $6.8 million from $6.3 million

Ordan Trabelsi, SuperCom's President and CEO, attributed impressive performance to the company's successful execution of its growth strategy

SuperCom (NASDAQ: SPCB), a global leading provider of traditional and digital identity solutions offering advanced safety, identification, and security solutions to governments, just released its financial and operating results for the third quarter of the 2023 financial year ("Q3 2023"). Of note was the 550% growth in EBITDA and a 74% growth in gross profit margins that Ordan Trabelsi, SuperCom's President and CEO, attributed to the "Successful execution of SuperCom's growth strategy" (https://ibn.fm/4lm4s).

SuperCom Ltd. (NASDAQ: SPCB) provides secured solutions for the e-government, IoT and cybersecurity sectors. Since 1988, the company has been a trusted global provider of traditional and digital identity offerings, providing cutting-edge electronic and digital security solutions to governments and organizations, both private and public, around the world.

SuperCom’s mission is to revolutionize the public safety sector worldwide through proprietary electronic monitoring technology, data intelligence, and complementary services.

The company is headquartered in Tel Aviv, Israel, with offices in California and other regions in the U.S.

Business Units

IoT and Connectivity

SuperCom IoT products and solutions provide advanced electronic monitoring solutions and services to criminal justice agencies, enabling customers to detect unauthorized movement of people, vehicles, and other monitored objects. The company provides an all-in-one, field-proven PureSecurity offender monitoring suite, accompanied by services such as GPS monitoring, home detention, domestic violence prevention, and more. The company’s services are specifically tailored to meet each client’s needs.

SuperCom’s proprietary Puresecurity suite of hardware, connectivity, and software components is the foundation for its criminal justice services and offerings. SuperCom is leveraging its extensive technology expertise to implement groundbreaking artificial intelligence (AI) technologies into various parts of its core offerings. By leveraging the power of AI, SuperCom’s PureSecurity platform can offer new abilities, such as amplified data analysis, predictive modeling, and streamlined automation – all geared toward optimizing decision-making and operational efficiency.

Competitive advantages of SuperCom’s technology include:

  • Long Battery Life (No Tag Charging Required)
  • Ultra Lightweight Form Factor
  • Next-Gen Location Tech
  • Protection of Domestic Violence Victims
  • And More

 

Cybersecurity

In 2015, SuperCom identified the cybersecurity market as a fast-growing space with significant advantages due to synergistic technologies and a shared customer base with its e-Gov and IoT business units. Consequently, SuperCom strategically acquired Prevision Ltd., a company with a strong presence in the market and a broad range of competitive cybersecurity services.

During the first quarter of 2016, SuperCom acquired Safend Ltd., an international provider of cutting-edge endpoint data protection guarding against corporate data loss and theft through content discovery and inspection, encryption methodologies, and comprehensive device and port control.

Both acquisitions significantly expanded the breadth of the company’s global cybersecurity capabilities.

e-Gov

Through proprietary e-government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance, and border control services, SuperCom has helped governments, and national agencies design and issue secured multi-identification, or Multi-ID, documents and robust digital identity solutions to their citizens, visitors, and lands.

The company has focused on expanding its activities in the traditional identification, or ID, and electronic identification, or e-Gov, markets, including the design, development, and marketing of identification technologies and solutions to governments in Europe, Asia, America, and Africa using SuperCom’s e-Government platforms.

Market Opportunity

Data from Berg Insight estimates the market for electronic monitoring solutions will grow from $1.2 billion in 2021 to $2.1 billion in 2026, marking a CAGR of 10.8% for the forecast period.

High recidivism rates, prison overcrowding, and soaring incarceration costs are some factors that are driving the electronic monitoring of offenders’ market growth.

An analysis by ReportLinker forecasts that the global cybersecurity market will grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, achieving a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving the cybersecurity market growth.

Management Team

Ordan Trabelsi is President and CEO of SuperCom. He has over 15 years of experience as CEO, growing high-tech companies globally. He also has experience in research and development and product innovation, as well as hands-on experience in cybersecurity, encryption, advanced mathematics, and mobile and internet network technologies. Prior to joining SuperCom, he served as co-founder and CEO of Klikot Inc., a global social networking company. He holds an MBA from Columbia University and a B.Sc. in Computer Engineering from The Technion: Israel Institute of Technology.

Barak Trabelsi is COO of SuperCom. He has expertise in big data, cyber, mobile, and internet network technologies, as well as extensive experience in product development and strategies. Prior to joining SuperCom, he served as Senior Product Manager at Equinox Ltd. Before that, he served for four years as VP of R&D at Sigma Wave, a wireless, security, and internet-focused company. He holds a B.Sc. in Computer Science and Business, as well as an MBA from Tel Aviv University.

Gil Alfi is VP of Sales at Safend Ltd., SuperCom’s cybersecurity subsidiary. He joined SuperCom in 2016 as VP of Business Development for Safend. He has more than 18 years of experience in technology companies. He served as an R&D team technology lead for more than seven years and as Director of Product Management for various telecom and wireless companies for more than 10 years. Prior to joining SuperCom, he served as Regional Sales Director at Safend, managing sales regions in Europe and Africa. He holds a B.Sc. in Computer Science and Mathematics and an M.Sc. in Computer Science from Bar-Ilan University.

SuperCom Ltd. (NASDAQ: SPCB), closed Tuesday's trading session at $0.367, off by 0.271739%, on 130,656 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.3416/$2.695.

Recent News

Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GTD0)

The QualityStocks Daily Newsletter would like to spotlight Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GTD0).

Sekur signed a major distribution agreement with a distributor in the Hashemite Kingdom of Jordan and The Republic of Iraq to distribute its entire Sekur Swiss-hosted private and encrypted communications platform

CEO Alain Ghiai is participating in weekly discussions about cybersecurity and internet security on Fox Business TV's Weekly Sekur Hack of the Week with multimedia journalist Ana Berry to raise awareness of recent cybersecurity threats

Sekur's 100% owned Swiss-hosted servers offer closed-loop secure encrypted products, including SekurVPN, SekurMail, SekurMessenger, and other services for businesses, governments, and individuals

Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FRA: GTD0), a cybersecurity and internet privacy provider of Swiss-hosted solutions for secure and private communications, recently announced that it has signed a major distribution agreement with a distributor in the Hashemite Kingdom of Jordan and The Republic of Iraq to distribute its entire Sekur Swiss-hosted private and encrypted communications platform. The agreement was signed with Solutions Communications & Security Systems and is valid for 12 months, with renewal options for an additional 12 months. The agreement also covers all of Jordan Iraq, specifically a telecom operator in Iraq called Asiacell Telecommunications Company (https://ibn.fm/TCVF8).

Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GTD0) is a Cybersecurity and Internet privacy provider of Swiss hosted solutions for secure and private communications. The company distributes a suite of encrypted e-mails, secure messengers and secure communication tools. Sekur Private Data Ltd. sells its products through its own website at www.Sekur.com, approved distributors, and telecommunications companies. Sekur Private Data Ltd. serves consumers, businesses and governments worldwide.

Customer information is completely confidential and safely stored in Switzerland using military grade security. All data, whether physical, network-based or encryption security, is stored in bank-approved, state-of-the-art ISO-certified data centers used by Swiss and global banks and most United Nations organizations, as well as many corporations and governmental organizations. All user data is protected by the Swiss Federal Data Protection Act and the Swiss Federal Data Protection Ordinance, which offer some of the strongest privacy protection in the world for both individuals and organizations.

The company owns 100% of its own infrastructure and, unlike its competitors, does not rely on third party cloud services like Amazon Web Services, Microsoft Azure Cloud or Google cloud infrastructure.

Sekur Private Data has chosen Switzerland to locate its data storage because of the country’s neutrality, independence, strong privacy laws, long standing political stability and excellent international relations. Switzerland is also home to several large multinational corporations and is ranked as having one of the strongest and most competitive economies in the world.

The company is headquartered in Toronto, Ontario.

Products

Sekur Private Data distributes a privacy communications suite offering encrypted and private email, the only Swiss-hosted privacy VPN, and a secure and private messaging application. All solutions cater to consumers, SMBs, enterprises and governments.

  • SekurMail® is an encrypted email service offering a private, safe and powerful tool to communicate with everyone, either within the Sekur ecosystem or outside. SekurMail protects personal information and communications from being accessed by unauthorized parties. Its encryption and other security measures prevent messages from being intercepted, modified or tampered with, either in transit or while stored. SekurMail empowers the client to access information and communicate with anyone in the world, regardless of geographical or political barriers.
  • SekurVPN® creates a secure, encrypted connection between the client’s device and the Internet, giving clients access to the web safely and privately by routing their connections through a server and hiding their online actions. All the data sent and received is hidden from prying eyes. This includes the clients’ Internet Service Providers, as well as potential hackers and even government surveillance agencies. It can also help clients bypass geographical restrictions and censorship.
  • SekurMessenger® is a Swiss-hosted private and secure messaging communications app providing secure and private chat, self-deleting chat, voice recording and file transfer via any mobile device, tablet or desktop computer. Communications are transmitted only within secure servers. It’s designed for organizations that need to protect their flow of information and secure their communications with customers and partners. SekurMessenger is designed to provide military-grade encryption and privacy by ensuring that only the sender and intended recipient can read the messages exchanged. It works for both licensed users of the app and intended message recipients who do not have the app.

Market Opportunity

An analysis from ReportLinker forecasts that the global cybersecurity market will grow from an estimated $173.5 billion in 2022 to $266.2 billion by 2027, recording a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors that are driving cybersecurity market growth, according to the report.

The global data privacy software market was estimated to be worth $1.68 billion in 2021 and is expected to grow from $2.36 billion in 2022 to $25.85 billion by 2029, achieving an eye-popping 40.8% CAGR during the forecast period, according to a Fortune Business Insights report titled ‘Data Privacy Software Market 2022-2029’.

The widespread shift toward remote working culture, evolving government data privacy regulations and the rapidly increasing adoption of Internet-of-Things devices are among the major factors propelling market growth, per the report.

Management Team

Alain Ghiai is founder, CEO and Director at Sekur Private Data. He also founded GlobeX Data S.A. (GDSA) in 2007 and has served as Director and CEO since then. He founded GlobeX Data Inc. (GlobeX US) in August 2012 and has served as Director and CEO since that time. He attended the California College of Arts in San Francisco, where he earned a Bachelor of Architecture. He has over 15 years of experience in the software industry and was instrumental in taking Sekur Private Data public in July 2019.

Scott Davis, CPA, CGA, is CFO at Sekur Private Data. He is also a partner at Cross Davis & Company LLP Chartered Professional Accountants. His experience includes CFO positions at several companies listed on the TSX Venture Exchange. He spent four years at Appleby as an Assistant Financial Controller. Prior to that, he spent two years at Davison & Company Chartered Professional Accountants as Auditor, five years with Pacific Opportunity Capital as Accounting Manager and two years at Jacobson Soda and Hosak, Chartered Professional Accountants. He obtained his CPA, CGA in 2003.

Learn more about the company’s management team by visiting its corporate page.

Sekur Private Data Ltd. (OTCQB: SWISF), closed Tuesday's trading session at $0.0589, off by 10.7576%, on 17,725 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.027/$0.1576.

Recent News

Canada Nickel Company Inc. (TSX.V: CNC) (OTCQX: CNIKF)

The QualityStocks Daily Newsletter would like to spotlight Canada Nickel Company Inc. (TSX.V: CNC) (OTCQX: CNIKF).

Canada Nickel Company Inc. (TSX.V: CNC) (OTCQX: CNIKF) is advancing the next generation of nickel-cobalt sulfide projects to deliver the metals needed to power the electric vehicle (EV) revolution and feed the high growth stainless steel market. The company is one of only a few new sources of potential supply outside Indonesia and China.

Canada Nickel possesses industry leading nickel expertise and is focused on low risk, well established mining jurisdictions. The company has launched wholly owned subsidiary NetZero Metals Inc. to develop zero-carbon production of nickel, cobalt and iron and has applied in multiple jurisdictions to trademark the terms NetZero Nickel, NetZero Cobalt and NetZero Iron. Canada Nickel is also pursuing development of processes to allow net zero carbon production of these elements.

Canada Nickel is currently anchored by its 100% owned flagship Crawford Nickel-Cobalt Sulfide Project with large-scale potential located in the heart of Ontario’s prolific Timmins-Cochrane mining camp, adjacent to major infrastructure.

The company believes the EV industry and many other consumer sectors have an urgent need for zero-carbon metal this decade, not in 20-25 years as contemplated by some resource companies. Canada Nickel also believes that nickel supplies from Indonesia and other Pacific island nations, typically controlled by Chinese-owned companies, are not the answer for batteries needed by GM, Ford and the European automakers working to develop and manufacture EV models.

The company is headquartered in Toronto.

Crawford Nickel-Cobalt Sulfide Project

The Crawford Nickel-Cobalt Sulfide Project is the largest sulfide discovery since the early 1970s and contains the fifth-largest nickel sulfide resource in the world, based on Measured & Indicated resources, according to the latest update. The Crawford project is expected to be one of the largest base metal mines in Canada based on results of a Preliminary Economic Assessment. Early projections by Canada Nickel estimate that the project has the potential to produce 50,000 tons of nickel per year. The company is now in the final stages of completing the project’s feasibility study.

The project is projected to produce 2.8 tons of CO2 per ton of nickel equivalent production, which is 89% lower than the industry average of 34 tons of CO2 per ton of nickel equivalent production.

The company is taking significant steps toward developing the Crawford project as a net zero carbon producer. In addition to harnessing the natural ability of the project’s geology to act as a carbon sink through spontaneous reaction of the host rock once exposed to atmospheric conditions called mineral carbonation, Canada Nickel has discovered a new way to enhance carbon capture, termed In Process Tailings (IPT) Carbonation. This act of conditioning the tailings with a concentrated stream of carbon dioxide before deposition has been demonstrated at lab scale to achieve carbon capture at a rate 8-12 times faster than naturally occurring sequestration, achieving more than 60% of the capture that had previously taken six days.

These latest results move the company further toward production of Net Zero Nickel™ and generation of 21 tonnes of CO2 credits per tonne of nickel, which would produce an estimated average of 710,000 tonnes of CO2 credits annually and 18 million total tonnes of CO2 credits over the expected life of mine. IPT Carbonation does not require complex new technologies and major process modifications and could encourage the development of a net zero carbon industrial cluster centered around the Crawford project.

Canada Nickel in January 2023 announced that its latest test work results support the incorporation of carbon capture and storage into the Crawford project. The company believes that utilization of existing process streams should allow IPT to be efficiently engineered and incorporated into the project’s flowsheet, with an integrated feasibility study for the project expected in the second quarter of 2023.

In December 2022, Canada Nickel announced its engagement on Deutsche Bank Securities Inc. (“Deutsche Bank”) and Scotiabank – two of the world’s leading investment banks with a broad base of mining and industrial expertise – as financial advisors for the equity component of the project financing for the Crawford project. In the same release, the company announced the completion of another significant permitting milestone by filing the detailed project description with the Impact Assessment Agency of Canada. Canada Nickel targets receipt of permits by mid-2025, with construction to immediately follow.

Additional Projects

The Reid Nickel Property is located just 16 kilometers southwest of Crawford, or 37 kilometers northwest of Timmins, and contains an ultramafic body with a target geophysical footprint of 3.9 square kilometers. Preliminary assay results from Canada Nickel’s summer/fall drilling program confirm the presence of mineralized dunite, as well as currently undefined higher-grade sections. Partial assay results confirm expected nickel grades. Nickel mineralization in serpentinized dunite was found in all 16 holes drilled to date.

The Sothman Nickel Property is located 70 kilometers south of Timmins. Five drill holes on the eastern half of the target anomaly confirmed the continuation of ultramafic lithologies, primarily peridotite, with moderate to strong serpentinization and variable amounts of mineralization throughout.

The company in December 2022 announced positive drilling results from its ongoing regional exploration campaign at its Reid and Sothman properties. These latest results continue to reinforce the success of Canada Nickel’s geophysical targeting approach and increase the probability of success at the company’s other 20-plus properties within its 42 square kilometers of geophysical targets.

Building on this momentum, Canada Nickel in December 2022 announced its entry into a deal to acquire a 100% interest in the past producing Texmont property situated between the company’s properties south of Timmins. As noted in the news release, the acquisition of the Texmont property provides near-term smaller scale production potential and is highly complementary to the company’s large-scale Crawford and regional nickel sulphide projects.

Market Opportunity

Global demand leaves the market fundamentally short of nickel in the medium- and long-term. Global primary nickel demand will likely reach 3 million tons in 2022, up from 2.4 million tons in 2020, according to the International Nickel Study Group (INSG).

The INSG says primary nickel production is forecast to hit 3.1 million tons in 2022. Indonesia, the world’s largest nickel miner, halted exports of unprocessed nickel ore in January 2020, due to a government-imposed ban. Indonesia has floated the concept of a nickel cartel whose member nations would exert influence over world nickel supply and prices, similar to OPEC’s pricing power over oil.

Benchmark Minerals, a leading EV supply chain research firm, projects that, by 2035, world demand for nickel will double from current levels to 6 million tons annually. That growing demand represents a need for new nickel production equivalent to 70 mines the size of Canada Nickel’s Crawford Project.

Management Team

Mark Selby is CEO and Director of Canada Nickel. He was formerly President and CEO of RNC Minerals, where he led a team that successfully raised over $100 million and advanced the Dumont nickel-cobalt project from initial resource to a fully permitted, construction-ready project. He has held senior management roles with Quadra Mining, Inco and Purolator Courier, and was a partner at Mercer Management Consulting. Since 2001, he has been recognized as one of the leading authorities on the nickel market. He graduated from Queen’s University with a Bachelor of Commerce.

Wendy Kaufman is CFO of Canada Nickel. She has 25 years of experience leading publicly listed mining companies in project financing, capital structuring, capital markets, accounting and internal controls, tax, and financial reporting and public disclosure. She was also previously CFO at Khiron Life Sciences Corp. and held CFO and senior finance positions at Pasinex Resources Limited, Primero Mining Corporation and Inmet Mining Corporation. She holds a Bachelor of Business Administration from Wilfrid Laurier University and is a Chartered Professional Accountant.

Steve Balch is VP Exploration at Canada Nickel. He is an Ontario registered geoscientist with 32 years of experience in geophysics, specializing in magnetic and electromagnetic methods. He founded Triumph Instruments and developed the AirTEM system, a multi-coil helicopter-borne EM system that is in use worldwide. He has also been active in borehole geophysics and helped develop new technologies including north-seeking gyros, temperature compensated induction conductivity probes, UAV-based magnetometers and high sensitivity magnetic gradiometers.

Christian Brousseau is VP Capital Projects at Canada Nickel. He is a professional engineer (P.Eng) with over 30 years of experience in engineering, design and construction in the Canadian mining industry, including six years as Project Director for the Dumont Project and three years as the Engineering and Construction Manager for Detour Gold. Prior to Detour, he held various construction management positions at Osisko’s Malartic Project and at Goldcorp’s Éléonore Project. He also spent eight years at Falconbridge supervising and managing various capital projects.

Canada Nickel Company Inc. (OTCQX: CNIKF), closed Monday's trading session at $2.05, up 3.0151%, on 73,251 volume with 375 trades. The average volume for the last 3 months is 57,207 and the stock's 52-week low/high is $1.04999995/$5.63000011.

Recent News

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services Global Corporation (SHRG), formerly Sharing Services Inc., is a diversified company dedicated to maximizing shareholder value, operating through two primary subsidiaries: Elepreneurs Holdings, a direct-selling company, and Elevacity Holdings, a products company. Headquartered in Plano, Texas, SHRG markets and distributes Elevate-branded health and wellness products through an independent sales force of distributors called Elepreneurs.

Proprietary Products

SHRG’s current exclusive Elevate product offerings are marketed under the Elevacity brand, so named to signify the company’s commitment to elevating lives.

The Elevate health and wellness product line consists of nutraceutical products that SHRG refers to as D.O.S.E., which stands for dopamine, oxytocin, serotonin and endorphins – all of which are key hormones proven to promote happiness and well-being.

Elevacity brand products are carefully formulated, chosen and designed to support a single objective: elevate the happiness and well-being of the consumer.

Global Network of Elepreneurs

Elevacity products are shared and sold by a growing international network of home-based entrepreneurs, called Elepreneurs, operated by Elepreneurs Holdings. This SHRG subsidiary provides basic and advanced programs for both new and experienced entrepreneurs who are focusing on their direct-sales careers.

SHRG’s high-performing independent sales force follows the company’s Blue Ocean selling strategy, an approach that encourages individuals to seek new markets, lead, and to “stop competing and start creating.” The Blue Ocean strategy is based on the book, “Blue Ocean Strategy,” written by Professor Renée Mauborgne, who notes that “the lesson here is that the best defense is offense, and the best offense… is to make a blue ocean shift and create your own blue ocean.”

Following this selling strategy, SHRG’s Elepreneurs are taught that, rather than competing directly in a competitive, direct-selling market, they should focus on making competitors irrelevant and succeeding in an uncontested marketplace.

In addition, SHRG’s Elepreneurs use the interactive, video-based VERB sales-marketing platform developed by Verb Technology Company Inc. The app utilizes proprietary interactive video data collection and analysis technology and provides next-generation customer relationship management, lead generation, and video marketing software applications.

Continued Momentum as Industry Leader

These selling strategies have resulted in sharp and consistent revenue gains. In the company’s 10-Q filed with the SEC for the three months ended Oct. 31, 2019, SHRG reported sales of $38.8 million for fiscal Q2 2019, an increase of 116% over sales of $17.9 million reported for the comparable quarter of 2018. Consolidated gross profit jumped by $16.2 million to $27.4 million for the same period compared to Q2 2018.

SHRG’s consolidated operating earnings were $3.9 million in the fiscal quarter ended Oct. 31, 2019, compared to $866,802 for the comparable period the prior year. Consolidated gross margin also grew 70.9% for the three months ended Oct. 31, 2019, compared to 62.2% the prior year.

These numbers are continuing a trend established over the past two years. In fiscal Q1 2019, SHRG achieved revenues of $35.4 million, more than double that of the comparable period in 2018. Even earlier, the company reported sales of $85.9 million for fiscal year ended April 30, 2019. This represents a nine-fold increase, or $77.5 million jump, over the company’s revenues of $8.4 million the prior year.

These numbers bring SHRG’s sales revenues since December 2017 — when the company’s Elevate product line was released — to an impressive cumulative total of $169 million.

Preparing for Success

SHRG is well prepared to continue and accommodate for this growth. The company recently expanded its corporate footprint by moving to a 10,000-square-foot facility in Plano, Texas, that offers ample room to expand as the company grows and flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

In addition, the company has a seasoned, expert leadership team in place, led by John “JT” Thatch. Thatch was appointed president and CEO of SHRG in March 2018, bringing to the company his expertise obtained from successfully starting, owning and operating several businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist SHRG as the company aims to expand and increase revenues.

Contact
469.304.9400 x 201
Info@SHRGinc.com
http://www.SHRGinc.com

Sharing Services Global Corporation (SHRG), closed the day's trading session at $1.01, up 23.17%, on 276,351 volume with 217 trades. The average volume for the last 3 months is 279,074 and the stock's 52-week low/high is $0.27/$2.54.

Recent News

Software Effective Solutions Corp. (OTC: SFWJ)

The QualityStocks Daily Newsletter would like to spotlight Software Effective Solutions Corp. (OTC: SFWJ).

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) is a global infrastructure and holding company in the cannabis industry. MedCana currently has five companies focused on pharmaceutical cannabis production, as well a software company focused on managing processes for plant-to-patient operations. The recent acquisition of an irrigation and greenhouse technology company has rounded out MedCana’s portfolio of holdings.

MedCana’s focus is on developing clients and companies in Latin America, initially in Colombia, and partnerships with laboratories, research facilities and hospitals throughout the world. MedCana is building the technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts to the world.

MedCana’s goal is to be the world’s premier resource for pharmaceutical cannabis products. The company believes its advantage is its global view and reach. From initial cultivation to final product, MedCana aims to help partners produce pharmaceutical CBD and other extracts that will have no equal.

The company’s mission is to utilize its technology to partner with and develop companies that provide premium pharmaceutical-grade cannabis extracts with absolute integrity, sustainability and social responsibility. MedCana’s team of pharmaceutical scientists includes some of the most respected chemists in the world. They aim to ensure that the company’s customers and partners create premium cannabis extracts that meet the growing worldwide demand. MedCana’s software is designed to ensure traceability and quality from seed to finished product.

MedCana is headquartered in Austin, Texas, with offices in Colombia.

Production

MedCana announced in May 2023 the beginning of full-scale production of non-THC cannabis for export to Europe in response to high demand in that market. This expansion comes after the successful completion of full crop cycle testing and infrastructure development at production sites in Columbia.

The recent acquisition of the assets of Tokan Corp., a software company focused on creating an enterprise resource planning (ERP) platform for the cannabis industry, and Eko2O S.A.S., a greenhouse and irrigation engineering company, has positioned MedCana for explosive growth in the region.

As a MedCana subsidiary, Eko2O SA will increase the company’s revenue potential in Central and South America. The subsidiary specializes in the construction and distribution of greenhouses and sophisticated irrigation platforms. A positive outlook has resulted from the company’s expansion as it investigates new opportunities for greenhouse and irrigation system installations in Panama and Uruguay. These opportunities are expected to accelerate Eko2O’s development and strengthen its position as a top supplier of innovative agricultural solutions in cannabis and other sectors that are quickly moving to high technology agricultural production.

In addition, MedCana has started talks with the government in Argentina about possible incentives for beginning operations in that country as part of its ongoing worldwide development strategy. Support from the Argentinean government and the start of new operations there would greatly increase MedCana’s market share in Latin America and solidify the company’s position as the market leader in the cannabis industry.

Market Opportunity

According to a report by Grand View Research, a San Francisco-based market research and consulting company, the global cannabis extract market was valued at $3.5 billion in 2022 and is expected to expand at a CAGR of 20% from 2023 to 2030 to be worth more than $15 billion.

Growing demand for cannabis extracts, including oils and tinctures, and the increased legalization of marijuana for the treatment of different chronic ailments like arthritis, Alzheimer’s, anxiety and cancer are driving the expansion of the industry. The marijuana derivative industry is flourishing due to a greater understanding of its various medical benefits.

Management Team

Jose Gabriel Diaz is CEO of MedCana. He has successfully built, grown and sold multiple telecom companies. He was senior vice president of sales at IP Communications, a national high-speed data provider. He also founded Reallinx, a national data carrier later sold to GTT Communications. Additionally, he is currently president of the A.E.M. Business and Entrepreneurship Association in Austin, Texas.

Claudio Jiménez Cartagena, QF, Ph.D. is Chief Scientific Officer at MedCana. He joined MedCana after working with Sosteli Pharma as Technical Director and serving as a director consultant for the Corporation for Agricultural Industrial Development at the University of Antioquia in Colombia. Before that, he worked as the scientific director at the Institute of Food Science & Technology. He holds a bachelor’s degree in pharmaceutical chemistry, a master’s degree in basic biomedical sciences and a doctoral degree in Environmental Engineering from the University of Antioquia.

Julián Alberto Londoño Londoño, Ph.D., is Senior Vice President of Operations at MedCana. He previously served as general manager for the Corporation for Agricultural Industrial Development, and as Chief Scientific Officer at Sosteli Pharma in the Resource Management Department. He has developed multiple U.S. patents, and recently served as senior advisor to the Secretariat of Agriculture Development for the Government of Antioquia. He holds a doctorate in Chemical Sciences from the University of Antioquia.

Software Effective Solutions Corp. (OTC: SFWJ), closed Tuesday's trading session at $0.035, even for the day. The average volume for the last 3 months is 2,258 and the stock's 52-week low/high is $0.000001/$0.14.

Recent News

Fintech Ecosystem Development Corp. (NASDAQ: FEXD)

The QualityStocks Daily Newsletter would like to spotlight Progressive Care Inc. (OTCQB: FEXD).

Fintech Ecosystem Development Corp. (NASDAQ: FEXD) is a special purpose acquisition company (SPAC) formed for the purpose of effecting one or more business combinations with an intent to focus on the financial technology sector.

The company’s mission is to create and grow a global financial services ecosystem to address unmet mobile money needs in developing and industrialized countries and markets. FEXD plans to achieve this by acquiring and merging with financial technology pioneers that have the potential to help establish its global fintech ecosystem, and by continuing the development of proprietary technologies and applications to keep the company at the forefront of the cashless society market.

Digital money is replacing physical cash. Consumers can buy products and services from anywhere in the world and make payments across borders. Parents can send money to students studying in other countries. Migrant workers are sending money to families in developing nations. Rural villagers without banks can send and receive money using their smartphones. FEXD is developing mobile transaction platforms, applications and services that are helping to implement these changes.

The company plans to offer a diverse portfolio of products and services to consumers and businesses in the United States, South Asia, East Asia, Africa, Europe and Latin America. Its growth strategy includes acquisition, innovation and market development.

FEXD is a Delaware corporation based in Collegeville, Pennsylvania. The company was launched in May 2021 by a management team led by Dr. Saiful Khandaker that has extensive experience in developing and managing financial service platforms and applications, primarily in the mobile money sector. FEXD is sponsored by Revofast LLC.

Acquisition Targets

In September 2022, FEXD announced definitive agreements for business combinations with Rana Financial Inc., a Georgia corporation, and Mobitech International LLC (dba Afinoz), a limited liability company organized in the United Arab Emirates. The agreements call for Rana and Afinoz to become wholly owned subsidiaries of FEXD, with the combined company expected to continue trading on the Nasdaq under existing ticker symbol ‘FEXD’. The mergers are expected to close in Q2 2023.

Rana Financial

Rana Financial is a licensed money transfer company founded in 2009. Rana provides fast and affordable online and mobile transfer of funds between the U.S. and Latin America. Rana has been providing money transfer services in the U.S. market for 13 years and has 30,000 active users. Rana’s money transfer business grew to 200,000 transactions in 2021. The merger agreement values Rana at an implied $78 million enterprise value.

Mobitech International LLC

Mobitech International LLC (dba Afinoz) is an artificial intelligence-enabled digital lending platform used by India’s leading banks, non-banking financial companies and fintech loan providers. Afinoz’s fintech platform supports enterprises making loans primarily to middle- and working-class borrowers via its website or through its mobile phone application. Afinoz’s platform makes loans available and affordable to millions of Indian workers and unbanked users by providing access at a low cost. Afinoz’s platform has more than 50 lending partners, and its database of registered users in India includes more than two million individuals. The merger agreement values Afinoz at an implied $120 million enterprise value.

Market Opportunity

According to analysis by global market research firm Mordor Intelligence, the worldwide financial technology market is valued at approximately $194 billion in 2023 and is projected to grow to nearly $500 billion by 2028, representing a CAGR of 18.97% for the forecast period. According to the report, various financial crises and the COVID-19 pandemic have fueled consumer adoption of, and investor interest in, fintech over the past several years.

Management Team

Dr. Saiful Khandaker is Founder, CEO and President of FEXD. He is Group CEO and founder of FAMA Holdings Inc., a global developer of fintech platforms, applications and services based in the U.S. with offices in the U.K., India, Bangladesh and Zambia. He is currently leading the development of the FAMACASH™ network, a global fintech ecosystem to provide fast, affordable mobile money services in underserved countries such as Bangladesh. Before founding FAMA, Dr. Khandaker spent more than two decades leading the development of software solutions for Fortune 100 companies and startups. He also helped numerous clients modernize their fintech services as Chief Technology Officer at Mi3. He holds a Doctor of Management in Organizational Leadership, a Master of Science in Technology Management, and a Bachelor of Science in Computer Information Systems.

Jenny Junkeer is CFO at FEXD. She is a Chartered Accountant with over 17 years of experience. As CEO of Junkeer New Era Consulting, she leads a team specializing in helping companies launch and optimize business operations in fast-changing industries. She has extensive experience helping organizations scale operations to maximize value. She is an Adjunct Association Professor at Deakin University in Australia, a board member of the Global Health Initiative Foundation, and Director of Implementation at ConnectCV. She holds a Bachelor of Commerce Degree (Honors) from Monash University.

FingerMotion Inc. (FEXD), closed Tuesday's trading session at $10.69, even for the day, on 3,240 volume. The average volume for the last 3 months is 18,048 and the stock's 52-week low/high is $10.14/$11.00.

Recent News

Turbo Energy S.A. (NASDAQ: TURB)

The QualityStocks Daily Newsletter would like to spotlight Turbo Energy S.A. (NASDAQ: TURB).

Turbo Energy S.A. (NASDAQ: TURB) designs, develops and distributes equipment for the generation, management and storage of photovoltaic energy in Spain, Europe and internationally.

Turbo Energy’s products include lithium-ion batteries and inverters. Additionally, the company recently launched its flagship product, the Sunbox, an all-in-one device that integrates most of the equipment required for a residential photovoltaic installation. The Sunbox is powered by AI and features a software system that monitors the generation, use and management of photovoltaic energy by analyzing large amounts of data related to energy generation, consumption, market prices and weather forecasts. This AI system optimizes battery usage, reducing electricity bills and providing peak-use reduction and uninterruptible power supply functions.

Turbo Energy currently sells its photovoltaic energy equipment primarily through distributors for residential consumers in Spain, but it possesses the expertise and international perspective to expand its product portfolio into industrial and commercial scale and markets, as well as advancing the internationalization process it has already started. The company plans to expand into the industrial photovoltaic sector with its new Sunbox, launched in 2023, in higher power and capacity variants. Its goal is to become a significant player in this sector and contribute to the growth of renewable energy solutions.

The company was incorporated in 2013 and is based in Valencia, Spain. It operates as a subsidiary of Umbrella Solar Investment S.A.

Products

Lithium-Ion Batteries

Turbo Energy is one of the leading companies that introduced lithium-ion batteries for photovoltaic energy storage in Spain. Primarily for the home energy storage market, the company’s batteries have capacities from 2.24 kWh to 5.1 kWh in 24 and 48 volts. In addition, its 48V / 5.1 kWh units are available in a dual battery system.

Inverters

The inverter converts the direct current produced by the photovoltaic panels into alternating current that can be used by household appliances. It also regulates battery charging and discharging based on energy needs and optimizes utilization of generated renewable energy. Turbo Energy currently offers multiple models that cover most household installations.

All-in-One Sunbox

This product incorporates inverters, batteries and the rest of the components necessary to operate and protect the photovoltaic installation. This saves installation cost and assembly and configuration time while preventing errors. Notably, the latest Sunbox models also offer an EV charging option.

Software System

In communication with the inverter, the company’s software monitors energy flows between the photovoltaic panels, household consumption, storage and an optional electric vehicle charging station. The software allows users to customize an automatic backup mode based on weather forecasts, or manually select which part of the battery will be reserved for possible power outages. It also allows the battery to be used in a peak shaving mode, which leverages AI to trigger battery power when grid energy is most expensive, effectively reducing the amount of high-cost power drawn from the grid.

Market Opportunity

According to a report by Fortune Business Insights, a global research and reporting firm, the solar energy storage battery market was estimated to be worth $3.33 billion in 2022 and is projected to reach a value of more than $20 billion by 2030, marking a CAGR of 24.2% over the forecast period.

These batteries are crucial components of renewable energy systems, allowing for the storage of excess electricity generated by solar panels, so it can be used during times of no or low sunlight. By storing energy and supplying it when needed, these batteries reduce reliance on the power grid and maximize self-consumption while helping users avoid peak electricity rates. They also contribute to the transition toward a cleaner and more sustainable energy future by enabling residential consumers and businesses to use solar power even when the sun is not shining.

Management Team

Enrique Selva Bellvís is the CEO and founder of the Umbrella Group. In addition, he serves as vice-president of the Valencian Association of Energy Sector Companies industry group. Before his career in the solar energy sector, he was the founder and CEO of Innova Ingenieros Consultores. He holds a degree in industrial engineering with a specialization in energy from the Polytechnic University of Valencia and completed the Management Development Programme at the IESE Business School.

Mariano Soria is the Chief Innovation Officer for the Umbrella Group and serves as General Manager of Turbo Energy. He was CEO of Punt Moble XXI S.L. and continues to serve on that company’s board. Before that, he was the General Manager of REJMAR S.A., a land development company. He received his degree in industrial engineering and industrial organization from the Polytechnic University of Valencia, and his MBA from the European University of Madrid.

Alejandro Moragues is CFO of Turbo Energy. Previously, he held the position of Senior Corporate Auditor for U.S. company Euronet Worldwide Inc. and was an external auditor for PricewaterhouseCoopers. He holds a bachelor’s degree in business administration and management from the Polytechnic University of Valencia.

Manuel Cercos is Chief Commercial Officer at Turbo Energy. Previously, he held positions at Técnicas Aplicadas en Baterías S.L., where he served as Sales Director and Sales Manager. Before that, he worked as a Sales Technician at DAISA.

Turbo Energy S.A. (NASDAQ: TURB), closed Tuesday's trading session at $1.8, off by 8.6294%, on 43,834 volume. The average volume for the last 3 months is 235,306 and the stock's 52-week low/high is $1.19/$7.90.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.